- Home
- GKOS vs FTDR Comparison
GKOS vs FTDR Comparison
Compare GKOS & FTDR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GKOS
- FTDR
- Stock Information
- Founded
- GKOS 1998
- FTDR 1971
- Country
- GKOS United States
- FTDR United States
- Employees
- GKOS N/A
- FTDR N/A
- Industry
- GKOS Medical/Dental Instruments
- FTDR Diversified Commercial Services
- Sector
- GKOS Health Care
- FTDR Finance
- Exchange
- GKOS Nasdaq
- FTDR Nasdaq
- Market Cap
- GKOS 5.4B
- FTDR 4.4B
- IPO Year
- GKOS 2015
- FTDR 2018
- Fundamental
- Price
- GKOS $82.38
- FTDR $65.37
- Analyst Decision
- GKOS Strong Buy
- FTDR Hold
- Analyst Count
- GKOS 12
- FTDR 4
- Target Price
- GKOS $128.58
- FTDR $59.75
- AVG Volume (30 Days)
- GKOS 698.2K
- FTDR 627.3K
- Earning Date
- GKOS 11-03-2025
- FTDR 11-03-2025
- Dividend Yield
- GKOS N/A
- FTDR N/A
- EPS Growth
- GKOS N/A
- FTDR 29.61
- EPS
- GKOS N/A
- FTDR 3.36
- Revenue
- GKOS $432,953,000.00
- FTDR $1,966,000,000.00
- Revenue This Year
- GKOS $28.79
- FTDR $14.54
- Revenue Next Year
- GKOS $25.65
- FTDR $6.49
- P/E Ratio
- GKOS N/A
- FTDR $19.37
- Revenue Growth
- GKOS 26.70
- FTDR 8.62
- 52 Week Low
- GKOS $77.10
- FTDR $35.61
- 52 Week High
- GKOS $163.71
- FTDR $67.26
- Technical
- Relative Strength Index (RSI)
- GKOS 35.40
- FTDR 61.76
- Support Level
- GKOS $80.52
- FTDR $63.31
- Resistance Level
- GKOS $95.32
- FTDR $67.26
- Average True Range (ATR)
- GKOS 2.82
- FTDR 1.99
- MACD
- GKOS -1.23
- FTDR 0.28
- Stochastic Oscillator
- GKOS 11.29
- FTDR 75.58
About GKOS Glaukos Corporation
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
About FTDR Frontdoor Inc.
Frontdoor Inc is a United States-based company that provides home service plans. It owns multiple home service brands including American Home Shield, HSA, OneGuard, and Landmark brands. Through its home service plans, the company helps its customers maintain their homes and protect against costly and unexpected breakdowns of essential home systems and appliances.